Nurix Therapeutics Inc reports results for the quarter ended May 31 - Earnings Summary

• Nurix Therapeutics Inc NRIX.OQ reported a quarterly adjusted loss of 52 cents​​ per share for the quarter ended May 31, higher than the same quarter last year, when the company reported EPS of -71 cents. The mean expectation of eighteen analysts for the quarter was for a loss of 73 cents per share. Wall Street expected results to range from -96 cents to -50 cents per share.

• Revenue rose 264.3% to $44.06 million from a year ago; analysts expected $17.01 million.

• Nurix Therapeutics Inc's reported EPS for the quarter was a loss of 52 cents​.

• The company reported a quarterly loss of $43.46 million.

• Nurix Therapeutics Inc shares had risen by 7.2% this quarter and lost 35.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.2% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

This summary was machine generated from LSEG data July 9 at 08:15 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)